Published on 4 May 2024 on Simply Wall St. via Yahoo Finance
Shareholders of G1 Therapeutics, Inc. (NASDAQ:GTHX) will be pleased this week, given that the stock price is up 13% to US$4.49 following its latest first-quarter results. Despite revenues of US$14m falling 4.0% short of expectations, statutory losses of US$0.20 per share were well contained, and in line with analyst models. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for G1 Therapeutics
earnings-and-revenue-growth